Page 74 - 南京医科大学自然版
P. 74
第45卷第7期
·972 · 南 京 医 科 大 学 学 报 2025年7月
Nat Commun，2023，14（1）：4893 ［29］JIANG Y F，FANG T，LU N，et al. Anti⁃PD1 rechallenge
［23］DING X，ZHANG W J，YOU R，et al. Camrelizumab plus in combination with anti⁃angiogenesis or anti⁃EGFR treat⁃
apatinib in patients with recurrent or metastatic nasopha⁃ ment beyond progression in recurrent/metastatic nasopha⁃
ryngeal carcinoma：an open ⁃ label，single ⁃ arm，phase Ⅱ ryngeal carcinoma patients［J］. Crit Rev Oncol Hematol，
study［J］. J Clin Oncol，2023，41（14）：2571-2582 2023，190：104113
［24］MO Y，PAN Y，ZHANG B，et al. Apatinib combined with ［30］HUA Y H，DONG R Z，JIN T，et al. Anti⁃PD⁃1 monoclo⁃
camrelizumab in the treatment of recurrent/metastatic nal antibody combined with anti⁃VEGF agent is safe and
nasopharyngeal carcinoma：a prospective multicenter effective in patients with recurrent/metastatic head and
phase Ⅱ study［J］. Front Immunol，2023，14：1298418 neck squamous cancer as second⁃line or beyond treatment
［25］JIANG Y F，CHEN C，LIU G Y，et al. Combination strate⁃ ［J］. Front Oncol，2022，12：781348
gy exploration for prior treated recurrent or metastatic ［31］GUO S S，YANG J H，SUN X S，et al. Reduced⁃dose ra⁃
nasopharyngeal carcinoma in the era of immunotherapy diotherapy for Epstein⁃Barr virus DNA selected staged Ⅲ
［J］. Sci Rep，2024，14（1）：1768 nasopharyngeal carcinoma：a single⁃arm，phase 2 trial［J］.
［26］CHENG C，ZHUGE L D，XIAO X，et al. Overcoming Eur J Cancer，2023，194：113336
resistance to PD⁃1/PD⁃L1 inhibitors in esophageal cancer ［32］LI Y J，XU T T，QIAN W，et al. Radiation⁃induced naso⁃
［J］. Front Oncol，2022，12：955163 pharyngeal ulcers after intensity modulated radiotherapy
［27］SUN J Y，ZHANG D K，WU S Q，et al. Resistance to PD⁃ in primary nasopharyngeal carcinoma patients：a dose ⁃
1/PD⁃L1 blockade cancer immunotherapy：mechanisms， volume⁃outcome analysis［J］. Oral Oncol，2018，84：1-6
predictive factors，and future perspectives［J］. Biomark ［33］NG W T，LEE M C H，CHANG A T Y，et al. The impact
Res，2020，8：35 of dosimetric inadequacy on treatment outcome of naso⁃
［28］ DING X，HUA Y J，ZOU X，et al. Camrelizumab plus pharyngeal carcinoma with IMRT［J］. Oral Oncol，2014，
famitinib in patients with recurrent or metastatic nasopha⁃ 50（5）：506-512
ryngeal carcinoma treated with PD⁃1 blockade：data from ［收稿日期］ 2025-02-07
a multicohort phase 2 study［J］. EClinicalMedicine， （本文编辑：蒋 莉）
2023，61：102043
（上接第962页）
hemopexin in protection of low ⁃ density lipoprotein ［20］ ROY N，GAUDET D，TREMBLAY G，et al. Association
against hemoglobin⁃induced oxidation［J］. Biochemistry， of common gene ⁃ smoking interactions with elevated
1996，35（40）：13112-13117 plasma apolipoprotein B concentration［J］. Lipids Health
［18］MATSUSHITA K，BALLEW S H，WANG A Y，et al. Epi⁃ Dis，2020，19（1）：98
demiology and risk of cardiovascular disease in popula⁃ ［21］FAN X M，ZHANG X L，LIU L C，et al. Hemopexin accu⁃
tions with chronic kidney disease［J］. Nat Rev Nephrol， mulates in kidneys and worsens acute kidney injury by
2022，18（11）：696-707 causing hemoglobin deposition and exacerbation of iron
［19］SCHMITT M，EWENDT F，KLUTTIG A，et al. Smoking is toxicity in proximal tubules［J］. Kidney Int，2022，102
associated with increased eryptosis，suicidal erythrocyte （6）：1320-1330
death，in a large population ⁃ based cohort［J］. Sci Rep， ［收稿日期］ 2025-02-26
2024，14：3024 （本文编辑：蒋 莉）
